This Web Site is committed to the memory of Janis Morrow.

   

 

 

 

 

 

VX950 Protease Inhibitor Telaprevir

2009-2007

Inhibitors Main Index

Latest News / Inhibitors & New Therapies

Vertex Pharmaceuticals Incorporated (Vertex) is a biotechnology company in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Telaprevir, lead drug candidate, is an oral hepatitis C protease inhibitor and one of the advanced of a new class of antiviral treatments in clinical development that target hepatitis C virus (HCV), infection.

Added Anti-Viral Halves Duration of Hepatitis C Treatment

 

 


 2009

November


Phase 2 Study of Telaprevir Administered q8h or q12h with Peginterferon Alfa-2a or Alfa-2b and Ribavirin in Treatment-Naïve Patients with Genotype 1 Hepatitis C: Final Results -

Telaprevir Vertex hep C protease inhibitor drug works well in twice daily dosing -

More than 80% of Hepatitis C Patients Treated in Study C208 Achieved an SVR with Telaprevir-Based Regimens - press release from Vertex

HCV Protease Inhibitor Telaprevir Demonstrates Good Efficacy in Both Treatment-experienced and Treatment-naive Patients

AASLD: High SVR Rates Seen with Telaprevir for Hepatitis C

More Than 80 Percent of HCV Genotype 1 Treatment-Naive Patients Achieved Sustained Virologic Response With Twice-Daily Telaprevir-Based Regimen

Nov 10


 


 
Drug Telaprevir Effective in Twice Daily Dosage as Well -
 
Vertex
Nov 01

After closely observing the hepatitis C drug Telaprevir in a study, Vertex Pharmaceuticals Inc., has confirmed that it works well when administered twice daily as well, instead of the earlier believed dosage of thrice daily. The study confirmed that the drug worked in over 80% of the patients when given two times a day as well.
All earlier tests carried out for Telaprevir had reported that the drug had to be given thrice a day, at regular 8 hour intervals, for it to effectively keep hepatitis C under control. The new study, however, has confirmed that even when given twice, at 12 hour intervals, it would work equally well.
81-85% of the patients involved in the study were earlier on a three times a day routine, shifting them to the twice daily routine, in combination with the standard hepatitis C treatments pegylated-interferon and ribavirin sustained the response they gave to the dosage when administered thrice. The data was presented at the meeting of American Association for the Study of Liver Diseases in Boston.
The study has, according to researchers involved, given much better results than initially expected. "I was expecting around 70 percent", Dr Patrick Marcellin, the study's lead investigator, said. The results of the study are being viewed as a big step in the history of hepatitis C treatment.

http://topnews.us/content/28087-hepatitis-c-drug-telaprevir-effective-twice-daily-dosage-well-vertex

 


October 


 
 
Oct 29
 
 
 
Oct 27
 
 
Oct 07
 
 
Oct 5
 
 
 
 

September


 

Vertex Pharmaceuticals Announces Publication of Telaprevir Abstracts for Presentation at the 60th AASLD Meeting

 
Sept 24 09
 
(Nasdaq: VRTX) today announced that sustained virologic response (SVR) data from Study C208, which evaluated twice-daily dosing of Vertex’s investigational hepatitis C virus (HCV) protease inhibitor telaprevir, will be presented in an oral presidential plenary session at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place Oct. 30 – Nov. 3, 2009 in Boston. Additionally, final results from PROVE 3 will be presented in an oral session at the conference. Results from a pooled analysis of PROVE 1 and PROVE 2 in "difficult-to-cure” patients, which include patients with factors potentially having an effect on SVR rates (viral load, race, age, sex, body mass index, genotype subtype and liver fibrosis stage), will be presented in a poster session.
 

The C208 presentation at AASLD will include SVR data (defined as undetectable HCV RNA at 24 weeks after completion of treatment) and represents the first SVR data for telaprevir-based regimens as part of a response-guided therapy trial design, similar to that being used in the Phase 3 trials of telaprevir. Study C208 is a four-arm, randomized, open label, Phase 2 clinical trial that was conducted by Tibotec in Europe in 161 treatment-naïve patients with genotype 1 HCV infection. Two different dosing regimens of telaprevir (750mg three-times daily or 1125mg twice daily) each were studied in combination with either peg-IFN-alfa-2a (PEGASYS®) or peg-IFN-alfa-2b (PEGINTRON™) and ribavirin (RBV), the standard therapies for chronic HCV infection.
 

The abstracts were published today and can be accessed on the AASLD website. In accordance with the AASLD embargo policy, the accepted abstract titles are provided below. Vertex is developing telaprevir in collaboration with Tibotec and Mitsubishi Tanabe Pharma.
 
 
Telaprevir Presentations

Twice-daily compared to three-times daily telaprevir-based therapy: Study C208
 
1. "Virological Analysis of Patients Receiving Telaprevir Administered q8h or q12h with Peginterferon-Alfa-2a or -Alfa-2b and Ribavirin in Treatment-Naïve Patients with Genotype 1 Hepatitis C: Study C208” (#194) will be presented in an oral presidential plenary session on Nov. 3, 2009 at 8:15 a.m. EST.
 
The authors of the study are Marcellin, Patrick; Forns, Xavier, Goeser, Tobias; Ferenci, Peter; Nevens, Frederik; Carosi, Giampiero; Drenth, Joost P.; De Backer, Koen; van Heeswijk, Rudolf; Luo Donghan; Picchio, Gaston; Beumont-Mauviel, Maria.
 

Telaprevir-based therapy in treatment-experienced patients:
 
PROVE 3 Final Analysis

2. "PROVE 3 Final Results and 1-Year Durability of SVR with Telaprevir-Based Regimen in Hepatitis C Genotype 1-Infected Patients with Prior Non-response, Viral Breakthrough or Relapse to Peginterferon-Alfa-2a/b and Ribavirin Therapy” (#66) will be presented in an oral parallel session on Nov. 1, 2009 at 6:00 p.m. EST. The authors of the study are McHutchison, John G.; Manns, Michael P.; Muir, Andrew J.; Terrault, Norah; Jacobson, Ira M.; Afdhal, Nezam H.; Heathcote, E. Jenny; Zuezem, Stefan; Reesink, Hendrik W.; Bsharat, Mohammad; George, Shelley; Adda, Nathalie; Di Bisceglie, Adrian M.

Telaprevir-based therapy in "difficult-to-cure” treatment-naïve patients: PROVE 1 & PROVE 2
 
Pooled Analysis

3. "Telaprevir, Peginterferon Alfa-2a and Ribavirin Improved Rates of Sustained Virologic Response (SVR) in "Difficult-to-Cure” Patients With Chronic Hepatitis C (CHC): a Pooled Analysis From the PROVE 1 and PROVE 2 Trials” (#1565) will be presented in a poster session on Nov. 3, 2009 at 8:00 a.m. EST. The authors of the study are Everson, Gregory T.; Dusheiko, Geoffrey M.; Ferenci, Peter; Alves, Katia; Bengtsson, Leif; McNair, Lindsay; McHutchison, John G.; Muir, Andrew; Pawlotsky, Jean-Michel; Zeuzem, Stefan.
 
About Telaprevir

Telaprevir (VX-950) is an investigational oral inhibitor of HCV protease, an enzyme essential for viral replication, and is one of the most advanced investigational antiviral agents in development that specifically targets HCV. Telaprevir is being evaluated as part of a global Phase 3 registration program in more than 2,200 treatment-naïve and treatment-failure patients.
Vertex retains commercial rights to telaprevir in North America. Vertex and Tibotec are collaborating to develop and commercialize telaprevir in Europe, South America, Australia, the Middle East and other countries. Vertex is collaborating with Mitsubishi Tanabe Pharma to develop and commercialize telaprevir in Japan and certain Far East countries.
 
About Hepatitis C

Hepatitis C is a liver disease caused by the hepatitis C virus, which is found in the blood of people with the disease. HCV, a serious public health concern affecting 3.2 million individuals in the United States, is spread through direct contact with the blood of infected people.1 Though many people with HCV infection may not experience symptoms, others may have symptoms such as jaundice, abdominal pain, fatigue and fever.1 Chronic HCV significantly increases a person's risk for developing long-term infection, chronic liver disease, cirrhosis or death.1
Current therapies for HCV typically provide sustained benefit in less than half of patients with genotype 1 HCV, the most common strain of the virus.2 If treatment is not successful and patients do not achieve an SVR, they remain at risk for progressive liver disease.1 In a recent study, the risk of liver failure, cancer or death following unsuccessful HCV treatment was assessed at 23% after 4 years, and 43% after 8 years.3
 
About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.

Lexiva is a registered trademark of the GlaxoSmithKline group of companies.

PEGASYS® is a registered trademark of Hoffman La Roche.

PEGINTRON™ is a trademark of Schering Corporation.
1Centers for Disease Control and Prevention. Hepatitis C Fact Sheet: CDC Viral Hepatitis. Available at: http://www.cdc.gov/hepatitis/HCV/PDFs/HepCGeneralFactSheet.pdf. Accessed,
September 24, 2009.

2 Strader DB, Wright T, Thomas DL, Seeff LB, AASLD practice guideline: diagnosis, management and treatment of hepatitis C. Hepatology: 2004(39):1147-1171
3Veldt et al, "Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis," Annals of Internal Medicine, 20 November 2007; 147: 677-684.

Vertex’s press releases are available at www.vrtx.com.
(VRTX – GEN)

erschienen am 24.09.2009 um 17:54 Uhr
 
 

August-July


Surveyed Physicians Will Treat Over 50 Percent of Hepatitis C Genotype 1-Infected Patients with the Protease Inhibitor Telaprevir
www.earthtimes.org

Forty Percent of Surveyed MCOs Will Place Only One Protease Inhibitor on Their Formularies, According to a New Report from Decision Resources

WALTHAM, Mass., Aug. 4 WALTHAM, Mass., Aug. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on profiles provided to them of emerging protease inhibitors, surveyed physicians indicate that they will prescribe Vertex/Johnson & Johnson/Mitsubishi Tanabe's telaprevir to more than 50 percent of their hepatitis C virus genotype 1-infected patients and will prescribe Schering-Plough's boceprevir to less than 30 percent of these patients. Although surveyed physicians perceive both telaprevir and boceprevir as efficacious drugs, they value (among other factors) telaprevir's shorter duration of treatment as compared to treatment duration using boceprevir.

The new Physician & Payer Forum report entitled Hepatitis C: Impact of and Receptivity to Novel Antivirals Among Payers and Prescribers finds that, among the surveyed physicians who indicate they will use both telaprevir and boceprevir for the treatment of hepatitis C virus genotype 1-infected treatment-naive patients, over 60 percent expect to start treatment for most or all of their patients with telaprevir. Surveyed physicians cite improved efficacy as the most important attribute influencing their prescribing decisions for hepatitis C virus.

"Eighty percent of the physicians we surveyed indicate that long-term efficacy is the most important attribute of novel therapies for hepatitis C virus," said Decision Resources Analyst Alexandra Makarova, M.D., Ph.D. "Nearly all surveyed physicians said that improvements in sustained virologic response in genotype 1-infected patients is the most important endpoint that will persuade them to use a novel treatment in place of currently-available therapies."

The report also finds that 40 percent of surveyed managed care organization's (MCOs) pharmacy directors indicate that they will place only one of the protease inhibitors on their formularies. Of these pharmacy directors, 10 percent expect to choose telaprevir while 30 percent say that they do not have a preference regarding telaprevir or boceprevir based on clinical data provided to them but will use cost as the basis for their selection.

Hepatitis C: Impact of and Receptivity to Novel Antivirals Among Payers and Prescribers is based on a U.S. survey of 84 gastroenterologists, 16 hepatologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

Webinar
Members of the media are welcome to attend our upcoming webinar entitled On the Verge of a Paradigm Shift in the Hepatitis C Virus Market: Physician and Payer Perceptions of Telaprevir, Boceprevir and Other Key Novel Antivirals. This webinar will be held on Thursday, September 3, 2009 at 10 a.m. U.S. Eastern Time. For more information, contact Christopher Comfort at 781-296-2597.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

 

 

Vertex Pharmaceuticals and Mitsubishi Tanabe Pharma Corporation Amend Agreement to Develop and Commercialize Telaprevir in Asia Aug 09

 

HCV Protease Inhibitor Telaprevir Improves Response, Halves Treatment Time For Hepatitis C Patients


New era in hepatitis C treatment

For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.

 

Results of the Phase IIb clinical trial – led by Duke Clinical Research Institute (DCRI) and 36 other sites, including NewYork-Presbyterian Hospital/Weill Cornell Medical Center – are published in the 30 April issue of the New England Journal of Medicine. The study was funded by Vertex Pharmaceuticals Incorporated, the maker of the drug telaprevir. The drug works by blocking an enzyme that the hepatitis C virus needs in order to replicate itself.

"These findings point the way to a new era in the treatment of hepatitis C," says Dr Ira M. Jacobson, a co-author of the study and chief of the Division of Gastroenterology and Hepatology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and the Vincent Astor Distinguished Professor of Clinical Medicine at Weill Cornell Medical College. "Not only does adding telaprevir make standard hepatitis C treatment more effective, but it makes it work much more quickly. We showed that the duration of therapy can be reduced from 48 weeks to 24 weeks for most patients. This could help reduce the potentially severe side effects of longer regimens with standard therapy."

The randomised, double-blinded trial followed 250 patients with untreated hepatitis C genotype 1. Researchers measured rates of sustained viral response or viral cure – an undetectable quantity of hepatitis C virus – 24 weeks after the end of completion of therapy. They compared a 12-week regimen of telaprevir combined with two different durations of the standard therapy – peginterferon alfa-2a and ribavirin – to a control group taking 48 weeks of standard therapy alone. Results showed that 67 percent of patients taking telaprevir in combination with standard therapy for 12 weeks followed by standard therapy alone for 36 weeks were cured; and 61 percent of those taking telaprevir in combination with standard therapy for 12 weeks followed by standard therapy alone for 12 weeks were cured. This is compared to 41 percent cure rate in the 48-week control group.

The study also showed that the percentage of patients who relapsed in the 24-week and 48-week telaprevir-based groups (2 percent and 6 percent, respectively) was much lower than the control group (23 percent).

The most common reported side effect in the telaprevir groups was rash, and contributed to some patients discontinuing the therapy.

Peginterferon alfa-2a is an antiviral drug given by injection that is also used to treat HIV and hepatitis B; it works in conjunction with a drug called ribavirin, a nucleoside analogue, to suppress the viral activity of hepatitis C. Side effects can include severe flu-like symptoms, depression, fatigue, insomnia and anaemia.

"Treating genotype 1 hepatitis C, the most common form of the infection in the United States, can be challenging because the side effects are difficult for many people to endure, the duration of treatment is long, and traditionally less than half of patients are able to be cured of their disease," says Dr Andrew Muir, a gastroenterologist at Duke Clinical Research Institute and a senior investigator on the study. "Even though telaprevir does produce side effects of its own, its addition to standard therapy was able to improve response rates and shorten the duration of treatment necessary – either one alone would have been an advance, and to be able to achieve both is a significant step in the right direction when it comes to treating hepatitis C."

(Source: Weill Cornell Medical College: New England Journal of Medicine: June 2009)


http://www.virtualmedicalcentre.com/news.asp?artid=13753&title=New-era-in-hepatitis-C-treatment&odr=&page=2


 


 

Telaprevir


Among several experimental directly-targeted antiviral agents for hepatitis C, the Vertex HCV protease inhibitor telaprevir (formerly VX-950) is furthest along in development. Final results from a pair of Phase 2b clinical trials – PROVE 1 and PROVE 2 – were published in the April 30, 2009 New England Journal of Medicine. PROVE 1, conducted in the U.S., included 250 previously untreated genotype 1 chronic hepatitis C patients (77% white), while PROVE 2, conducted in Europe, included 334 participants (94% white). Participants were randomly assigned to receive standard therapy with 180 mcg/week Pegasys plus 1000-1200 mg/day ribavirin for 48 weeks or various regimens containing telaprevir (1250 mg on day 1 then 750 mg every 8 hours) plus Pegasys, with or without ribavirin.

In PROVE 1, SVR rates were significantly higher in patients who received telaprevir/Pegasys/ribavirin for 24 or 48 weeks, but those who took the three-drug regimen for only 12 weeks did no better than those on standard dual therapy (SVR 61%, 67%, 35%, and 41%, respectively). Only 7% of patients taking telaprevir experienced viral breakthrough. In the small subgroup of African-American patients (a population that responds more poorly to interferon-based therapy), those taking telaprevir had a four-fold higher SVR rate compared with standard therapy (44% vs. 11%). Discontinuation due to adverse events was about twice as likely in the telaprevir arms compared with standard therapy (21% vs. 11%), with skin rash being the most common reason for stopping. In PROVE 2, the 12- and 24-week triple regimens performed better than standard dual therapy, which in turn worked better than the 12-week telaprevir/Pegasys regimen without ribavirin (SVR 60%, 69%, 46%, and 36%, respectively). Again, rash, itching, and anemia were more common in the telaprevir arms.

In an accompanying editorial, J. Hoofnagle wrote that these trials "suggest that the addition of telaprevir to the combination of peginterferon and ribavirin will increase rates of sustained virologic response in patients with chronic hepatitis C due to infection with HCV genotype 1 from approximately 45% to as high as 65% and will permit therapy to be limited to 24 weeks, thus avoiding the expense and side effects of prolonged therapy."

Telaprevir has also been studied in prior pegylated interferon/ribavirin nonresponders and relapsers in the PROVE 3 trial. As reported at the 2009 European Association for the Study of the Liver (EASL) meeting in April, patients receiving telaprevir/Pegasys/ribavirin had significantly higher SVR rates those taking standard dual therapy, but the 24-week arm had a higher relapse rate than the 48-week arm, indicating that longer treatment may be better for treatment-experienced patients.

http://www.hcvadvocate.org


June


EASL 2009
Alan Franciscus, Editor-in-Chief

http://www.hcvadvocate.org/news/newsLetter/2009/advocate0609.html#1

The European equivalent of the American Association for the Study of Liver Diseases (AASLD) conference is the European Association for the Study of the Liver (EASL).  This year’s EASL conference included a wealth of information about studies that have been conducted on drugs in development to treat hepatitis C.  This article will focus on coverage of the drugs furthest along in the development cycle—telaprevir and boceprevir as well some exciting news on the development of HCV therapeutic vaccines that are in early clinical development. 

Telaprevir
In previous Phase II studies of Vertex’s telaprevir, an HCV protease inhibitor, it has been reported that SVR rates have been as high as 69% in people with HCV genotype 1 who have never been treated (treatment naïve).  Retreatment with pegylated interferon plus ribavirin in people who did not achieve a sustained virological response (SVR-undetectable HCV RNA (viral load) 24 weeks post treatment) with a previous course of pegylated interferon plus ribavirin is very important because they constitute a large group of people with HCV who are in the most need for newer HCV medicines that will improve the chances for successful response to treatment.  At EASL results of a phase II study of patients who did not achieve an SVR and who were treated with the combination of telaprevir /Pegasys/ ribavirin were reported and the results are very encouraging.   

There were three groups in the study:

Group A:  telaprevir, Pegasys, ribavirin for 12 weeks followed by Pegasys plus ribavirin for an additional 12 weeks (total treatment duration = 24 weeks).

Group B:  telaprevir, Pegasys, ribavirin for 24 weeks followed by Pegasys plus ribavirin for an additional 24 weeks (total treatment duration = 48 weeks). 

Group C:  Pegasys plus ribavirin for a total treatment duration of 48 weeks (standard of care). 

A total of 453 patients were enrolled and received at least one dose of the study drug.  (See Table 1 for SVR results)

 

Definitions of Prior Non-Response

Non-responders: people who never achieved an undetectable HCV RNA (viral load) during or at the end of HCV treatment.

Relapsers:  people who became HCV viral load undetectable during to the end of the HCV treatment period, but who later became HCV RNA (viral load) positive during the follow-up period. 

Breakthroughs:  people who achieved an undetectable HCV viral load during treatment, but who later had detectable HCV viral load before the end of the treatment period.

 

Table 1: SVR results by type of prior response:

 

Group A (TVR12/PR24)

Group B (TVR24/PR48)

Group C (PR48)

Non-responders

39% out of 66 patients

38% out of 64 patients

9% out of 68 patients

Relapsers

69% out of 42 patients

76% out of 41 patients

20% out of 41 patients

Breakthroughs

57% out of 7 patients

50% out of 8 patients

40% out of 5 patients

Total

51% out of 115 patients

52% out of 113 patients

14% out of 114 patients

Safety
Vertex reported that the side effects were consistent with prior studies of telaprevir/Pegasys/ribavirin.  Seventeen out of 339 patients (5%) discontinued therapy due to skin rash and three out of 339 patients (1%) due to anemia.    Growth factors were allowed in the study but only two out of 339 patients in the telaprevir groups were given growth factors to treat anemia.  

Comment:
Even though the total number of patients in the study was small, the overall SVR rates are impressive.  Another study, the REALIZE study, has been launched by Tibotec (Vertex’s European partner) that will enroll about 650 treatment-experienced patients, and the results should give us a better picture of the effectiveness of a regime that includes the combination of telaprevir, pegylated interferon and ribavirin, as well as hopefully confirm the prior results.   

Boceprecir
The final results of the SPRINT-1 study of boceprevir, an HCV protease inhibitor used in combination with PegIntron plus ribavirin, were also released at EASL.  The patients in the study were HCV genotype 1 patients who had never been treated (treatment naïve) for hepatitis C.

The study had two parts:
Part 1:  To evaluate boceprevir (800 mg – three times a day), PegIntron and ribavirin in standard doses with different treatment durations.  Total of 5 different treatment groups – two of the arms also had a lead-in phase with PegIntron plus ribavirin (without boceprevir).  In this part of the study the various treatment regimes were compared to PegIntron plus ribavirin (standard of care (control group)) for 48 weeks.   (520 patients total)

Part 2: To evaluate boceprevir, PegIntron and ribavirin treatment: two different doses of ribavirin (800-1400 mg/day vs. 400-1000 mg/day); 48 weeks of treatment with the triple combination of boceprevir/PegIntron/ribavirin.  No lead-in phase.  (75 patients total)

Part 1 Results
An SVR rate of 75% (77 out of 103 patients) was highest in the arm that received the lead-in of PegIntron plus ribavirin for 4 weeks followed by 44 weeks of boceprevir /PegIntron/ ribavirin (total treatment duration = 48 weeks) vs. an SVR of 38% in the group that received the current standard of care therapy of PegIntron plus ribavirin.  In the group that received the lead-in of PegIntron plus ribavirin for 4 weeks followed by 24 weeks of the triple combination of boceprevir/PegIntron/ribavirin (total treatment duration = 28 weeks) the SVR rates were only 56%, which confirmed that the optimal treatment duration for the triple combination (boceprevir, PegIntron, ribavirin) therapy is 48 weeks. 

Safety Results
Treatment discontinuations due to side effects in Part 1 of the study were between 9 and 19% in the boceprevir arms compared to 8% in the arm without boceprevir.  The most common side effects reported were fatigue, anemia, nausea and headache. 

Anemia (hemoglobin decreasing to less than 10 g/dL) occurred in about 50% of people in the boceprevir arms compared to about 1/3 in the arm without boceprevir.  Erythropoietin (EPO-growth factor) was allowed in the study—26% of patients used EPO in the arm without boceprevir compared to 39-51% who used EPO in the groups that received boceprevir. 

Part 2 Results
In Part 2 (low dose ribavirin) it was found that the SVR rate was 36% vs. 50% in the standard dose group (both in combination with boceprevir and PegIntron).  This information confirms that standard doses of ribavirin are needed to increase SVR rates even with the addition of boceprevir.  

Comments
The results are impressive—75% SVR rates.  However, the increase in anemia seen in the patients who received boceprevir is a cause for concern that could limit the usefulness of boceprevir.  Another concern is that EPO was allowed and used in the clinical trials.  The use of EPO raises many concerns including:  

  • EPO is not currently approved by the FDA to treat HCV treatment-related anemia.  It is unlikely that the vast majority of patients who develop anemia from HCV treatment will be able to use EPO since there are strong warnings about the use of EPO that are now listed on the FDA approved EPO package insert.  

  • If EPO is used, will it be covered by most insurance companies?  This seems highly unlikely in the light of the warnings about and the cost of EPO.   

  • How did the use of EPO affect the treatment outcome?  Would more patients have dropped out of the study if EPO wasn’t used?  If so, that could decrease the listed SVR rates. 

  • Does boceprevir now have an advantage over the other HCV drugs in development that have not been able to or rarely used EPO?

  • Does boceprevir now have a disadvantage over the other HCV drugs in development because EPO was used in the clinical trials?  Will physicians decide not to prescribe boceprevir due to anemia if patients do not have access to the use of EPO?

We may find out some of the answers when phase III studies are completed, but most likely the real answers will come when and if boceprevir is approved by the FDA to treat HCV. 

Erythropoietin or EPO:
Erythropoietin or EPO is a hormone that is naturally produced by the kidneys, and to a lesser extent by the liver, that helps stimulate the bone marrow to produce red blood cells that will increase the oxygen-carrying capacity of the blood.  Synthetic EPO (brand name Epogen, Procrit) is an injectible medicine that has been approved by the Food and Drug Administration (FDA) to treat anemia caused by kidney failure, the HIV medication AZT, and cancer.   Most people have heard of EPO related to its illegal use as a performance-enhancing drug by some athletes.  In 2007, the FDA issued a Public Health Advisory and required a black box warning on the product information labeling about the potential health risks of using EPO.
Box

HCV Vaccines
The discovery of protective or therapeutic vaccines has proven difficult, but reports from EASL on various therapeutic vaccines are encouraging.  Therapeutic vaccines work to stimulate the immune system to fight an infection and may have a use in ‘boosting’ the effectiveness of current and future medications to treat hepatitis C. 

TG4040:  Results from a phase I study were released and it was found that 6 out of 15 patients given the therapeutic vaccine, TG4040, had a viral load reduction of 0.5 to 1.4 log10 IU/mL from baseline.  The next step in the development process is a new clinical trial of TG4040 in combination with pegylated interferon plus ribavirin.  The new trial is expected to begin in 2010.  

GI-5005:  Treatment with GI-5005, a therapeutic HCV vaccine (plus pegylated interferon/ribavirin) was compared to pegylated interferon/ribavirin (without GI-5005).  The combination that included GI-5005 was found to produce 8% to 12% higher rates of HCV viral load reductions at twelve weeks in HCV genotype 1 treatment-naïve patients compared to those in the group who did not receive GI-5005. 

ChronVac-C DNA vaccine:  Data on the first DNA vaccine was released at EASL.  In a proof of concept study, 12 HCV genotype 1 treatment-naïve patients were given various doses of the therapeutic vaccine.  In 4 out of 6 patients who received the two highest doses there were viral load reductions exceeding 0.5 log10 that lasted for 2 weeks to greater than 10 weeks.  The HCV viral load reductions correlated with specific immune response thereby satisfying the proof of concept.

In the trials of HCV vaccines listed above, the vaccines were safe and well-tolerated.

In addition to the above studies, there were many reports on drugs being developed to treat hepatitis C.  These drugs are in very early development and a summary of the results can be found on the HCV Advocate Drug Pipeline web page.
 

 

 


May

New HCV Drugs


  New England Journal of Medicine Publishes Promising Data from PROVE 1 and PROVE 2 Studies of HCV Protease Inhibitor Telaprevir

By Liz Highleyman

http://www.hivandhepatitis.com/hep_c/news/2009/051209_a.html

Several directly targeted oral antiviral agents are currently under study for the treatment of chronic hepatitis C virus (HCV) infection, with the HCV NS3/4A serine protease inhibitor telaprevir (formerly known as VX-950) expected to be the first out of the pipeline. Telaprevir is being developed by Vertex Pharmaceuticals in collaboration with Tibotec and Mitsubishi Tanabe Pharma.

Presented previously at medical conferences, final data from a pair of Phase 2b clinical trials of telaprevir -- PROVE 1 and PROVE 2 -- were published for the first time in the April 30, 2009 New England Journal of Medicine. The 2 reports and an editorial are available free online.

PROVE 1 was conducted in the U.S. and PROVE 2 in Europe; therefore they had somewhat different patient populations. Both studies assessed previously untreated participants with HCV genotype 1. PROVE 1 included 250 participants at some 40 U.S. sites; most (63%) were men, the mean age was 48 years, and 77% were white. PROVE 2 included 334 participants in Austria, France, Germany, and the U.K.; again, about 60% were men, but the mean age was slightly younger, at 44 years, and almost all (94%) were white. For reasons that are not well understood, white patients respond better to interferon-based therapy than black patients.

Study participants were randomly assigned to receive standard therapy using 180 mcg/week pegylated interferon alfa-2a (Pegasys) plus 1000-1200 mg/day weight-adjusted ribavirin for 48 weeks (effective in about 50% of genotype 1 patients), or else various regimens containing telaprevir (1250 mg on day 1 then 750 mg every 8 hours) or a matching placebo plus Pegasys with or without ribavirin:

Telaprevir + Pegasys + ribavirin for 12 weeks (T12PR12) -- PROVE 1 and PROVE 2;

Telaprevir + Pegasys with no ribavirin for 12 weeks (TP12) -- PROVE 2 only;

Telaprevir + Pegasys + ribavirin for 12 weeks, followed by Pegasys + ribavirin without telaprevir for an additional 12 weeks (T12/PR24) -- PROVE 1 and PROVE 2.

Telaprevir + Pegasys + ribavirin for 12 weeks, followed by Pegasys + ribavirin without telaprevir for an additional 36 weeks (T12/PR48) -- PROVE 1 only;

Pegasys + ribavirin without telaprevir for 48 weeks (standard-of-care control arm, PR48) -- PROVE 1 and PROVE 2.

The primary outcome in both studies was sustained virologic response (SVR), or undetectable HCV RNA 24 weeks after completion of treatment.

PROVE 1 Results:

SVR rates were significantly higher in the 24-week and 48-week triple therapy arms compared with standard therapy, but no better in the arm that received only 12 weeks of treatment:
 

67% in the T12PR48 group;
61% in the T12PR24 group;
41% in the PR48 group;
35% in the T12PR12 group.

Viral breakthrough occurred in 7% of patients receiving telaprevir.

African-American patients had a 4-fold higher SVR rate in the telaprevir arms compared with the standard therapy arm (44% vs 11%), but this subgroup was too small to have much statistical validity.
 

The rate of discontinuation due to of adverse events (AEs) was about twice as high in the 3 arms that received telaprevir (collectively 21%) compared with the standard therapy arm 11%).

Skin rash was the most common reason for discontinuation of telaprevir.

Based on these findings, the study authors concluded, "Treatment with a telaprevir-based regimen significantly improved sustained virologic response rates in patients with genotype 1 HCV, albeit with higher rates of discontinuation because of adverse events."

PROVE 2 Results:

The SVR rate was significantly higher in the 48-week telaprevir triple therapy arm compared with standard therapy, and the 12-week triple regimen performed better than the short regimen without ribavirin:
 

69% in the T12PR48 group;
60% in the T12PR12 group;
46% in the PR48 group;
36% in the T12PR12 group.

The AEs that occurred more frequency in the telaprevir arms were pruritus (itching), rash, and anemia.

"In this phase 2 study of patients infected with HCV genotype 1 who had not been treated previously, one of the three telaprevir groups had a significantly higher rate of sustained virologic response than that with standard therapy," the researchers concluded. "Response rates were lowest with the regimen that did not include ribavirin."

"Currently available therapies for patients infected with HCV can be difficult to tolerate and less than half the patients who start the yearlong treatment regimen achieve the ultimate goal of having an undetectable level of virus in their bodies," PROVE 1 lead investigator John McHutchison said in a press release issued by Vertex. "In these Phase 2 clinical trials, up to 69 percent of patients in the 24-week telaprevir-based treatment arm had undetectable virus levels after 24 weeks, and even though telaprevir does produce side effects of its own, its addition to standard therapy allowed us to shorten the duration of treatment."

Telaprevir has also been studied in treatment-experienced patients who did not achieve sustained response with a prior course of pegylated interferon plus ribavirin (both complete non-responders and relapsers).

As reported at the recent annual meeting of the European Association for the Study of the Liver (EASL 2009), treatment groups receiving a telaprevir-containing regimen had significantly higher SVR rates than the standard therapy arm, but the 24-week arm had a higher relapse rate than the 48-week arm, leading the investigators to suggest that the longer course may be more appropriate for treatment-experienced patients.

Telaprevir is now being tested in a larger population of treatment-naive patients in the Phase 3 ADVANCE trial, focusing on 24-week response-guided regimens consisting of either 8 or 12 weeks of telaprevir plus pegylated interferon and ribavirin for 24 or 48 weeks.

Editorial

In an accompanying editorial, Jay Hoofnagle of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) reviewed progress in the field of hepatitis C treatment over the past 25 years, from conventional interferon alfa monotherapy, to today's standard-of-care pegylated interferon plus ribavirin (which reduces the risk of relapse), to the forthcoming directly targeted oral anti-HCV agents.

"These phase 2 trials suggest that the addition of telaprevir to the combination of peginterferon and ribavirin will increase rates of sustained virologic response in patients with chronic hepatitis C due to infection with HCV genotype 1 from approximately 45% to as high as 65% and will permit therapy to be limited to 24 weeks, thus avoiding the expense and side effects of prolonged therapy," Hoofnagle wrote.

"An obvious question is why telaprevir was given for only 12 weeks and not continued with the peginterferon and ribavirin for a total of 24 or 48 weeks," he continued. "The reason was the side effects. In both studies, telaprevir was associated with an increased rate of anemia, nausea, diarrhea, pruritus, and rash. The rashes tended to be severe, to arise after 8 weeks of treatment, and to increase in frequency thereafter. The nature and cause of the rashes were not elucidated."

Hoofnagle noted that the SVR rates seen in PROVE 1 and PROVE 2 might not be as high as expected based on preliminary studies, in which a triple regimen of telaprevir/pegylated interferon/ribavirin "led to decreases of the HCV RNA to undetectable levels within a few weeks in almost all patients."

End-of-treatment response rates using telaprevir in these trials were similar to those achieved with the use of peginterferon plus ribavirin, but sustained response rates were greater in the triple therapy arms. Therefore, he suggested, "the enhanced response rates with telaprevir may be due to the prevention of viral breakthrough and relapse and may occur only in patients who have at least a partial response to peginterferon."

"Telaprevir appears to be a material advance in the therapy of hepatitis C, beginning a new era of treatment -- an era of antiviral agents developed specifically to target this virus," Hoofnagle concluded. "Other HCV-specific agents, including other protease inhibitors, helicase and polymerase inhibitors, and molecular agents that interfere with viral replication, are likely to follow. Combinations of these new agents with drugs currently in use may ultimately provide effective therapy for all patients with hepatitis C, the promised goal of decades of research."

5/15/09

References

JG McHutchison, GT Everson, SC Gordon, and others. Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection. New England Journal of Medicine. 360(18): 1827-1838. April 30, 2009. (Free full text).

C Hézode, N Forestier, G Dusheiko, and others. Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection. New England Journal of Medicine. 360(18): 1839-1850. April 30, 2009. (Free full text).

J Hoofnagle. A Step Forward in Therapy for Hepatitis C [Editorial]. New England Journal of Medicine. 360(18): 1899-1901. April 30, 2009. (Free full text).

Other Source

Vertex Pharmaceuticals. New England Journal of Medicine Publishes Landmark Clinical Studies of the Investigational Hepatitis C Virus Protease Inhibitor Telaprevir. Press release. April 29, 2009.


Vertex's Telaprevir

Vertex had a fairly quiet EASL conference, mainly because telaprevir is in the middle of phase III studies that won't have data available until next year. Still, the company did present previously disclosed data showing that telaprevir is capable of significantly improving cure rates in the most difficult-to-treat patients who had failed prior treatment with the current standard drug regimen for hepatitis C -- a 48-week course of long-acting interferon plus ribavirin.

This data keeps telaprevir ahead of its hepatitis C rivals because no other drug has yet shown the ability to improve the cure rates for both patients new to therapy as well as those who have failed prior therapy.

Telaprevir was the "butt" of some negative EASL chatter due to an anecdotal report that the drug was causing severe anal itching in patient(s). One EASL attendee described the side effect as "fire in the hole."

All jokes aside, itchy rash is a well-known and documented side effect of telaprevir, but there have been no confirmed reports of anal pruritis (the medical term for anal itching) in any of the telaprevir studies presented to date. In fact, patient discontinuation rates due to telaprevir-induced rash appear to be on the decline, as doctors and patients learn how to better manage the side effect.

 This should lead to higher cure rates for telaprevir in the ongoing phase III studies compared to the already high rates seen in the phase II trials.


Additional Information


New England Journal Of Medicine Publishes Landmark Clinical Studies Of The Investigational Hepatitis C Virus Protease Inhibitor Telaprevir

 Telaprevir Effective for Genotype 2 But Not For Genotype 3 -

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection...PROVE1 in NEJM 4/2009

TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY

 

 

A Step Forward in Therapy for Hepatitis C EDITORIAL -

NEJM April 30 2009
 
Jay H. Hoofnagle, M.D.
From the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
 
"An obvious question is why telaprevir was given for only 12 weeks and not continued with the peginterferon and ribavirin for a total of 24 or 48 weeks. The reason was the side effects. In both studies, telaprevir was associated with an increased rate of anemia, nausea, diarrhea, pruritus, and rash. The rashes tended to be severe, to arise after 8 weeks of treatment, and to increase in frequency thereafter. The nature and cause of the rashes were not elucidated....
 
...A second question is why the rate of sustained virologic response to the combination of telaprevir, peginterferon, and ribavirin was not higher. In preliminary studies, this combination led to decreases of the HCV RNA to undetectable levels within a few weeks in almost all patients.11,12,13 Nevertheless, at the end of the treatment period in these two trials, only 57% and 70% of patients had undetectable HCV RNA levels, end-of-treatment response rates that can be achieved with the use of peginterferon and ribavirin alone.5,6,7 Because the relapse rates were lower among patients receiving telaprevir than among those receiving standard therapy, the sustained virologic response rates were higher with telaprevir. Therefore, the enhanced response rates with telaprevir may be due to the prevention of viral breakthrough and relapse and may occur only in patients who have at least a partial response to peginterferon....
 
....Telaprevir appears to be a material advance in the therapy of hepatitis C, beginning a new era of treatment - an era of antiviral agents developed specifically to target this virus. Other HCV-specific agents, including other protease inhibitors,14 helicase and polymerase inhibitors, and molecular agents that interfere with viral replication,15 are likely to follow. Combinations of these new agents with drugs currently in use may ultimately provide effective therapy for all patients with hepatitis C, the promised goal of decades of research."

 
The therapy of hepatitis C began almost 25 years ago with a small trial of recombinant human interferon alfa.1 The rationale for using interferon was its broad antiviral effects and the suspicion that it might be active against the still-undiscovered agent of non-A, non-B hepatitis. Indeed, interferon had striking effects, lowering serum aminotransferase levels and, in a proportion of patients, inducing a lasting improvement in serum enzyme levels. Not until the discovery of the hepatitis C virus (HCV) were the effects of interferon understood; treatment resulted in a decrease in HCV RNA levels, which led to a sustained absence of virus in a proportion of patients.2 The difficulty was that interferon required parenteral injections, had multiple adverse effects, and resulted in a poor overall response rate. Nevertheless, interferon was approved for use for hepatitis C treatment in the United States in 1992.
 
The second important advance in hepatitis C therapy came with the use of ribavirin. Ribavirin is a nucleoside analogue known to have activity against several flaviviruses. When HCV was identified as a flavivirus, ribavirin was an obvious treatment choice. Ribavirin had little effect on serum HCV RNA levels but led to improvements in aminotransferase levels and histologic characteristics of the liver.3 More importantly, when combined with interferon, ribavirin increased the rate of sustained virologic response.4 Interferon and ribavirin given in combination for 48 weeks yielded rates of sustained virologic response of 40 to 50%, two to three times those obtained with interferon alone.3 Ribavirin was approved for use as an adjunct to interferon therapy of hepatitis C in 1998.
 
A third advance in therapy of hepatitis C came soon thereafter, with the introduction of pegylated forms of interferon that allowed for once-weekly (rather than thrice-weekly) injections. Peginterferon yielded higher rates of sustained virologic response than standard interferon: 45 to 55% after a 48-week course of peginterferon and ribavirin.5 The response rates varied according to HCV genotype. Among patients infected with genotypes 2 and 3 (approximately 25% of patients in the United States), rates of sustained virologic response were 70 to 80% and were achieved with a 24-week course and reduced doses of ribavirin.6 In contrast, rates of sustained virologic response among patients infected with genotype 1 (approximately 70% of patients in the United States) were less satisfactory, ranging from 40 to 50% and requiring 48 weeks of full doses of ribavirin. In some populations, response rates were even lower, with rates of approximately 25 to 30% among blacks.7 Higher doses and longer courses of therapy increased rates of sustained virologic response minimally and usually were associated with increased side effects.3 Peginterferon was approved in the United States in 2001.
 
Almost 10 years later, a fourth advance in hepatitis C therapy is still awaited but now may be close at hand. Two articles in this issue of the Journal describe results of phase 2 trials involving telaprevir (formerly known as VX-950).8,9 Telaprevir is a specific inhibitor of the HCV protease and is one of several molecules developed according to a rational drug design based on the molecular structure of HCV.10 Telaprevir is peptidomimetic, meaning that it resembles the HCV polypeptide that is cleaved by the viral protease, a necessary step in replication. However, telaprevir has an electrophilic "serine-trap warhead" that forms a covalent bond with the catalytic serine residue of the protease, blocking its activity. Telaprevir, an agent developed specifically to target HCV, represents a new era of therapy for hepatitis C.
 
Telaprevir has profound effects on HCV replication in cell culture and in animal models.10 In phase 1 studies of chronic hepatitis C, a 1-to-2-week course of telaprevir lowered HCV RNA levels by 2 to 5 log10 IU per milliliter.11 As expected, this short-term therapy was followed by a rebound in viral levels after the drug was stopped. Furthermore, telaprevir resistance appeared rapidly, and viral levels trended upward during the last days of treatment. The combination of telaprevir and peginterferon appeared to provide more profound viral suppression and less viral resistance.12,13 Some patients treated with peginterferon and ribavirin for a full 48 weeks after the short course of therapy with telaprevir, peginterferon, and ribavirin had a sustained virologic response.
 
These phase 1 studies led to the design of the two trials reported here, by McHutchison et al. in the United States (ClinicalTrials.gov number, NCT00336479 [ClinicalTrials.gov] )8 and HŽzode et al. in Europe (NCT00372385 [ClinicalTrials.gov] ).9 The trial designs were somewhat complex. Telaprevir was given for 12 weeks only, in combination with peginterferon alfa-2a with or without ribavirin, which were given for either for the same 12 weeks or for a total of 24 or 48 weeks. The control group received the standard therapy of peginterferon and ribavirin for 48 weeks. Standard therapy yielded rates of sustained virologic response of 41% and 46%, respectively. In comparison, telaprevir given for 12 weeks combined with peginterferon and ribavirin given for 24 weeks yielded response rates of 61% and 69%, both significant increases over the responses to standard therapy.
 
The other regimens tested had less satisfactory results. The stopping of all therapy at 12 weeks yielded lower rates of sustained virologic response than seen with continuation of therapy through 24 weeks, and the use of peginterferon and telaprevir without ribavirin was associated with high rates of relapse. Finally, in the study by McHutchison et al., the continuation of peginterferon and ribavirin for a total of 48 weeks, including the initial 12-week course of all three agents, was no more effective than the 24-week regimen (rate of sustained virologic response, 67% and 61%, respectively). These phase 2 trials suggest that the addition of telaprevir to the combination of peginterferon and ribavirin will increase rates of sustained virologic response in patients with chronic hepatitis C due to infection with HCV genotype 1 from approximately 45% to as high as 65% and will permit therapy to be limited to 24 weeks, thus avoiding the expense and side effects of prolonged therapy.
 
An obvious question is why telaprevir was given for only 12 weeks and not continued with the peginterferon and ribavirin for a total of 24 or 48 weeks. The reason was the side effects. In both studies, telaprevir was associated with an increased rate of anemia, nausea, diarrhea, pruritus, and rash. The rashes tended to be severe, to arise after 8 weeks of treatment, and to increase in frequency thereafter. The nature and cause of the rashes were not elucidated.
 
A second question is why the rate of sustained virologic response to the combination of telaprevir, peginterferon, and ribavirin was not higher. In preliminary studies, this combination led to decreases of the HCV RNA to undetectable levels within a few weeks in almost all patients.11,12,13 Nevertheless, at the end of the treatment period in these two trials, only 57% and 70% of patients had undetectable HCV RNA levels, end-of-treatment response rates that can be achieved with the use of peginterferon and ribavirin alone.5,6,7 Because the relapse rates were lower among patients receiving telaprevir than among those receiving standard therapy, the sustained virologic response rates were higher with telaprevir. Therefore, the enhanced response rates with telaprevir may be due to the prevention of viral breakthrough and relapse and may occur only in patients who have at least a partial response to peginterferon.
 
Telaprevir appears to be a material advance in the therapy of hepatitis C, beginning a new era of treatment - an era of antiviral agents developed specifically to target this virus. Other HCV-specific agents, including other protease inhibitors,14 helicase and polymerase inhibitors, and molecular agents that interfere with viral replication,15 are likely to follow. Combinations of these new agents with drugs currently in use may ultimately provide effective therapy for all patients with hepatitis C, the promised goal of decades of research.
 
No potential conflict of interest relevant to this article was reported.

www.natap.org


April-March

New Drugs In Devolvement


Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VCH-222 Abstracts for Presentation at EASL Annual Meeting

Vertex Pharmaceuticals Strengthens HCV Drug Development Portfolio, Adds Novel Polymerase Inhibitors to Shape New Combinations with Telaprevir
 

Vertex Acquires VCH-222 and VCH-759, Two Experimental Oral HCV Polymerase Inhibitors

Vertex Outlines 2009 Business Priorities: Registration Programs in Hepatitis C and Cystic Fibrosis; Balanced Investment to Maintain Financial Strength

Vertex / ViroChem:
I
n early March 2009, Vertex announced that it will acquire Canadian biotech ViroChem for $100 million in cash and about 10.7 million shares of Vertex common stock.  ViroChem has two HCV non-nucleoside polymerase inhibitors, VCH-222 and VCH-759.  ViroChem’s HCV polymerase inhibitors are in early development and will now be developed by Vertex and combined with Vertex’s HCV development pipeline.  Vertex announced that it expects to begin a combination study of telaprevir with a ViroChem HCV polymerase inhibitor in the second half of 2009.  In addition to the combination study with telaprevir, Vertex announced that it is also planning additional studies of ViroChem’s HCV polymerase inhibitors in combination with pegylated interferon plus ribavirin.
Source:  Company Press Release.

http://www.hcvadvocate.org/news/newsLetter/2009/advocate0409.html#3

Feb-Jan

Telaprevir Phase 3 Studies Update - (01/12/09)


 

December 2008


 
 

New HCV Drugs at AASLD: Vertex is Focus at Hepatitis C Meeting

http://www.thestreet.com    
 
SAN FRANCISCO -- Every six months, hepatitis C researchers from around the world gather to discuss new ways of combating the serious liver disease. In recent years, these biannual confabs have largely revolved the development of a new, more potent class of drug that promises to bring cures to a larger percentage of hepatitis C patients than ever before.
 
Like previous meetings, the one that kicked off over the weekend here will have scientists (and the Wall Street investors and analysts who follow their work closely) talking a lot about Vertex Pharmaceuticals'(VRTX Quote - Cramer on VRTX - Stock Picks) drug telaprevir.
 
Data being presented will show once again telaprevir's impressive ability to directly interfere with and eliminate the virus that causes hepatitis C in patients who have failed previous treatments and in those who are being treated for the first time.
 
Competitors to Vertex are here too. Schering-Plough will present data on the ability of its experimental drug boceprevir to eliminate the hepatitis C virus in previously untreated patients. Companies with drugs in less advanced clinical trials, including Pharmasset, InterMune, Boehringer Ingelheim, Johnson & Johnson, Merck and Pfizer, also will be presenting new or updated data. (from Jules: there are several drugs in earlier development: the BMS NS5A inhibitor is a new class, looks very potent, and the first patient data is presented at AASLD; Genelabs has HCV NNRTIs in early development and this company was just bought by GSK; Novartis already had purchased the rights to a Genelabs HCV NNRTI; Anadys has a HCV NNRTI; Abbott has a nuke, NNRTI, and a protease program; Pfizer is presenting data on their new HCV NNRTI at AASLD; NNRTI may be able to be combined because two different NNRTIs might bind at different sites, yet to be studied in patients; at EASL in the Spring data was reported in patients on weekly IV dosing of silibin and it was very potent, an update is presented at AASLD; Idenix has several HCV drugs in early development; Nitazoxanide (NTZ) is being studied in patients, it has enhanced synergy with interferon and has shown good SVR rates in early studies with peginterferon; other companies have additional drugs in early development that will be presented at EASL 2009 and later
 
For many biotech investors, Vertex remains a central focus of these hepatitis C meetings because the company is in the midst of conducting two large phase III studies of telaprevir, with the first results expected in the first half of 2010.
 
Vertex intends telaprevir to become the first new hepatitis C drug approved in years, and one that will dramatically increase the cure rate for the disease, and do so in half the time of currently approved drugs. If the plan succeeds, Vertex will grab a large share of a multi-billion dollar commercial market opportunity.
 
There are no sure things in drug development, which is why the value of Vertex shares swing rather wildly, especially as new data is unveiled and questions -- new and old -- are raised at these gatherings of hepatitis C researchers.
 
Is telaprevir the best of this new crop of hepatitis C drugs? Will Schering-Plough catch up? Are second-generation drugs already in development more potent and more convenient than telaprevir? And if so, does that leave Vertex vulnerable?
 
Much of the most important data at this year's annual meeting of the American Association for the Study of Liver Disease will be presented Monday and Tuesday. However, the veil on some of this data has been lifted already. Here's a recap of what's available so far:
 
Vertex:
 
Telaprevir stands apart from other experimental hepatitis C drugs, including Schering-Plough's boceprevir, because it appears capable of curing the disease in large numbers of patients who have failed previous treatments. (from Jules: so far the data in the Vertex press releas shows 40% of previous null-responders to peg/RBV achieved an SVR with telaprevir+peg?RBV, which means 60% fail and can get drug resistance. Will you then be able to use a protease inhibitor again in the future along with multiple oral new drugs in combination, where the best chance of cure will occur??? We don't know the answer to that question.)
 
A phase II study known as PROVE 3 showed that 52% of patients treated with telaprevir had undetectable levels of virus in their systems 12 weeks after treatment was stopped, according to interim data from the study being presented at the meeting. Vertex had previously announced some of these results last June.
 
Patients were enrolled in PROVE 3 if they had failed previous treatment with 48 weeks of pegylated interferon and ribavirin, the current standard hepatitis C therapy. These difficult-to-cure patients were then retreated with 12 weeks of telaprevir plus interferon and ribavirin, followed by another 12 weeks of interferon and ribavirin alone for a total of 24 weeks of therapy.
 
Breaking down the 52% overall result further, 73% of patients who had relapsed after receiving the standard treatment were able to drop their viral loads to undetectable levels, while 41% of patients who had not responded at all to previous treatment likewise achieved undetectable viral loads.
 
PROVE 3 also used as a control patients who were retreated a second time with the standard interferon and ribavirin. So far, just 30% of these patients have undetectable levels of virus after 36 of a planned 48 weeks of retreatment. Final data on these control patients is not ready, but far fewer are likely to reach undetectable viral loads in the observation period following treatment, based on historical data.
 
In a previous phase II study known as PROVE 2, which enrolled treatment-naive hepatitis C patients, telepravir helped 69% of patients reach undetectable viral loads 24 weeks after treatment. By comparison, 46% of patients treated with interferon and ribavirin alone saw the level of virus fall below undetectable levels.
 
The telaprevir regimen used in PROVE 2 was the same as that used in PROVE 3 -- 12 weeks of telaprevir plus interferon and ribavirin followed by another 12 weeks of interferon and ribavirin alone.
 
In all previous and ongoing clinical trials, patients take telaprevir every eight hours, or three times a day. For competitive reasons, Vertex would like twice-daily telaprevir. Interim data to be presented at the meeting suggests twice-daily telaprevir is possible and could be better than standard therapy. However, three-times-a day telaprevir still appears to be the most potent dosing schedule.
 
Schering's drug boceprevir is posting equivalent cure rates to that of telaprevir in treatment-naive patients, although the most effective treatment cycle is twice as long.
 
According to results from the phase II SPRINT-1 study released here, 74% of patients on a 48-week boceprevir regimen saw their viral loads fall below the level of detection 12 weeks following the cessation of treatment. (from Jules: this data is in treatment-naivs, the data in treatment-experienced will not be as good as Vertex's but again combination therapy with a least 2 oral drugs achieving a big log reduction in viral load plus peg/RBV will be the best regimen, particularly for patients who have failed previous therapy and who have reduced response to peg/RBV, which includes African-Americans in particular, genotype. Perhaps the best way to evaluate one's ability to respond to triple telaprevir therapy is to conduct a peg/RBV lead-in phase then add the oral drug. This study will be conducted so lets see the outcomes.)
 
These patients began treatment with four weeks of interferon and ribavirin (a lead-in period) followed by 36 weeks of boceprevir in combination with interferon and ribavirin.
 
For patients without the four-week lead in, 66% saw their virus fall below detectable levels.
 
Using a shorter, 28-week boceprevir regimen, 55% and 56% of patients achieved undetectable viral loads with no lead in treatment, or a lead-in treatment, respectively.
 
Schering-Plough is currently conducting two phase III studies of boceprevir in treatment-naive and treatment-resistant patients.
 
Pharmasset
 
Pharmasset's drug R7128 hasn't been as broadly tested as those from Vertex and Schering-Plough, but the data generated so far has shown the drug to be very effective at tamping down the hepatitis C virus.
 
The biggest question mark hanging over the drug to date is toxicity. At an investor event Sunday, Pharmasset officials for the first time discussed in some detail the emergence of kidney toxicity seen in a safety study in monkeys.
 
According to Pharmasset, the monkey kidney toxicity is reversible and did not cause permanent damage. More importantly, no such problem has been observed in the short human studies of R7128 conducted to date.
 
Pharmasset is conducting a longer, six-month safety test of R7128 in monkeys, but at this point the company doesn't believe that the Food and Drug Administration will stop further human studies from starting in the first quarter of next year.
 
Still, judging by the volume of questions from investors at Sunday's meeting that began with the words, "I'd like to get back to those monkey studies ..." the issue isn't one that Wall Street is ready to put entirely to rest.
 
Pharmasset is developing R7128 with partner Roche, which just last week was forced to halt development of a rival hepatitis C drug derived from its own laboratories because of unacceptable safety problems.
 
This Roche setback upped the value of R7128. If the drug's safety can be verified, Pharmasset will be a hepatitis C company to watch.


 

New Study:  Telaprevir in Treatment Experienced Patients
—Alan Franciscus, Editor-in-Chief

On October 15, 2008 Tibotec announced that it will begin screening patients for a large phase III study to evaluate the combination of telaprevir, pegylated interferon plus ribavirin in treatment experienced patients who did not achieve a sustained virological response to a previous course of treatment with pegylated interferon plus ribavirin.  Tibotec is Vertex’s commercial partner that is conducting clinical trials outside of the United States, Canada and Mexico.

This worldwide study will enroll about 650 HCV patients.  According to the company press release the U.S. centers have begun screening patients, and other global study centers are expected to begin the screening process within the next couple of weeks.  The study will include null responders, partial responders and relapsers. 

The REALIZE Study

The study will include 3 arms:

1.   Telaprevir dosed at 750 mg q8h (every eight hours) for 12 weeks in combination with standard doses of pegylated interferon plus ribavirin, followed by 36 weeks of treatment with pegylated interferon plus ribavirin alone;

2.   Delayed start arm – 4 weeks of treatment with pegylated interferon plus ribavirin, followed by telaprevir dosed at 750 mg q8h for 12 weeks in combination with standard doses of pegylated interferon and ribavirin, followed by another 32 weeks of pegylated interferon and ribavirin alone;

3.   Control Arm – standard doses of pegylated interferon plus ribavirin dosed for 48 weeks.

The study has been named REALIZE (Re-treatment of Patients with Telaprevir-based Regimen to Optimize Outcomes).

Currently, Vertex is conducting another large phase III study of telaprevir in combination with pegylated interferon plus ribavirin for the treatment of genotype 1 treatment naïve patients called the ADVANCE trial.  The ADVANCE trial is expected to enroll about 1050 patients in the U.S., Europe and certain other countries.  It is expected that the results from the ADVANCE study will be used to apply to the Food and Drug Administration for marketing approval of telaprevir in the U.S.  

For more information about the ADVANCE and REALIZE studies visit www.clinicaltrials.gov

Source:  Company Press Release

 


Additional December News...........

December 2008


AASLD: New Drugs in Development

A Study of Telaprevir Combined with Peginterferon Alfa-2a and Ribavirin in Patients with Well-documented Non-response or Relapse After Previous Peginterferon Alfa-2a and Ribavirin Treatment: Interim Analysis

New Study:  Telaprevir in Treatment Experienced Patients

New HCV Drugs at AASLD: Vertex is Focus at Hepatitis C Meeting

A Phase 2b Study of Telaprevir with Peginterferon-Alfa-2a and Ribavirin in Hepatitis C Genotype 1 Null and Partial Responders and Relapsers Following a Prior Course of Peginterferon-Alfa-2a/b and Ribavirin Therapy: PROVE3 Interim Results

Telaprevir in Combination with Peginterferon-a-2a With or Without Ribavirin in the Treatment of Chronic Hepatitis C Treatment-Naive Genotype 1: Final Results of the PROVE2 Study (conducted in Europe) -


NOV


AASLD: New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection -

Vertex Treatment May Also Help Non-Responders

Denise Treating With Protease Inhibitor Telaprevir Vertex-950

 On this Web Site : Terry was in the boceprevir trial 6 mth SVR!! 

Or read it on our Forum : TERRY boceprevir trial six month SVR

Phase 2 Study of Telaprevir Administered q8h or q12h with Peginterferon Alfa-2a or Alfa-2b and Ribavirin in Treatment-naive Patients with Genotype 1 Hepatitis C: Week 12 Interim Results - (11/26/08)
 
A Study of Telaprevir Combined with Peginterferon Alfa-2a and Ribavirin in Patients with Well-documented Non-response or Relapse After Previous Peginterferon Alfa-2a and Ribavirin Treatment: Interim Analysis - (11/20/08)
 
Telaprevir in Combination with Peginterferon-a-2a With or Without Ribavirin in the Treatment of Chronic Hepatitis C Treatment-Naive Genotype 1: Final Results of the PROVE2 Study (conducted in Europe) - (11/06/08)
 
A Phase 2b Study of Telaprevir with Peginterferon-Alfa-2a and Ribavirin in Hepatitis C Genotype 1 Null and Partial Responders and Relapsers Following a Prior Course of Peginterferon-Alfa-2a/b and Ribavirin Therapy: PROVE3 Interim Results - (11/06/08)


Oct-Sept


Vertex CEO preparing for '09 early telaprevir hepatitis C drug launch -

Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir-based Regimen in Genotype 1 Hepatitis C Patients Who Failed Prior Treatment -

EASL 2008-New Drugs Bottom Line 

HCV Protease Inhibitor Telaprevir, PROVE1 Study: final results of a phase 2 study with peginterferon plus ribaviron in treatment-naive patients with hepatitis C -

A Study of Telaprevir (TVR) with Peginterferon Alfa-2a (P) and Ribavirin (R) in Subjects with Well-Documented Prior PR Null Response, Non-Response or Relapse: Preliminary Results

Vertex and Tibotec Start Phase 3 Study of Telaprevir for Treatment-Naive Genotype 1 Hepatitis C Patients

Telaprevir plus Pegylated Interferon and Ribavirin Allows Shorter Therapy for Patients with Genotype 1 HCV

Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment


May-April


Vertex reports promising hepatitis C drug results

Telaprevir-Based PROVE Studies Show Significantly Higher SVR Rates in Treatment-Naive Genotype 1 Hepatitis C Patients in Half the Time of Current Treatments

Vertex Telaprevir HCV Protease Inhibitor Could Be A Winner; 2.5 million untreated/undiagnosed

New HCV Protease Inhibitor Telaprevir: 80% of Treatment-Experienced Patients Achieve Early Viral Response

Vertex to Start Phase 3 Trials of HCV Protease Inhibitor Telaprevir (VX-950) - 2/01/08

Data On Investigational Compounds Being Co-Developed By Tibotec For The Treatment Of Chronic Hepatitis C Presented At EASL 2008


Denise Treating With Protease Inhibitor Telaprevir Vertex-950

Read more on our message boards

The whole story

I can't believe I only have 3 days of Riba left!  It was so great to fill up my pill dispenser for the week and be able to leave some days empty!!! 

It's been a rough ride(who's treatment isn't?!?) but if I can hold onto that UD it will all have been worth it.

Iam1a, Stage2, Grade 1-2.  I was in a 48 week arm.  The first 24 weeks I took the standard treatment as well as the Telaprevir.  The last 24 weeks have been standard treatment only.

They did not allow rescue drugs in the Prove 3 trial and I became anemic real quick...just like the last time I treated.  Since Procrit wasn't an option they had to dose reduce/discontinue my Riba for most of the trial.  I was only on full dose Riba for a few of the 48 weeks.  It's been shown that Riba is a necessary part of the cocktail so I was VERY nervous.  I wasn't able to get any VL results until my 24 week results.  At that time I found out that I went from 12,500,000 on my start date to <30 by week 4! The first time I treated with SOC I didn't have a 2 log drop by week 13 and stopped.  At that time  I started with a much lower VL of 2,380,000.  That just give's you an idea of how powerful these PI's are.

Vertex is continuing trails with the Telaprevir as well as 2 other PI's.

Vertex has submitted some late extracts regarding Prove 3 preliminary results to be presented at the EASL meeting in April.  I have a feeling it's going to be more great news from Vertex. 

I learned everythingI needed to get me through the past 48 weeks right here on J&F and will always be grateful for this site and the people here.

I owe Karen a huge debt of gratitude.  She has been there for me every day and when I didn't feel like talking to ANYONE, Karen was the exception.  Thank you my friend.  Now, we need to get you on a PI so we can start planning that trip!

A friend of mine has declared Thursday as "All bad things gone and only good things to come,day!";-)

Thanks again to everyone for the well wishes and hope to start posting again as my system starts to clear.

If anyone has any questions about the Prove 3 trail feel free to email me through my profile.

BTW, I LOVE VERTEX!!!

Denise...next stop SVR...

UPDATE April 30th 08

I just got the news today that my 4 week post VL is UD!!

I wish they could speed things up so these PI's would become available for everyone.

I feel fantastic!  My energy level is higher than it's been in years.  The only leftover sx of treatment is a little brain fog....things like forgetting what I'm talking about mid-sentence and turning on my left signal to turn right :-)  Other than that, I feel great!

SVR party in September!!!! 

The whole story

 

Update June 26th

Hi Everybody!

I got the news today that 12 weeks after my treatment in the Vertex Prove 3 trial ended I am still UNDETECTED!! Yippee!!!!!!!  I return for my 24 week post treatment labs on Sept. 12.

I have had an amazing recovery from treatment.  I feel great!  I pop out of bed early every morning like I have a spring in me. I'm ready to go, go, go!  I'm sleeping better than I have in years. 

I wish they would hurry up and get these PI's on the market so that everyone can have access to them.

The next time I post my labs I am planning to post a big SVR.  It's almost party time ;-)

Denise

Sep 20th

Denise is SVR she did it !!!!


We Have A List of our Members on Treatment posted in our forum.

We keep the list updated with milestones, side effects and blood work. You can visit our forum  as a Guest .

If you wish to join our site in order to communicate with us please click here

By joining our forum you will also be able to enter our chat room and post messages.

 


2007-2006




Telaprevir plus Pegylated Interferon
Is Effective against Both Wild-type and Drug-resistant HCV Strains   - 8/17/07

Mutations That Confer Resistance to HCV Protease Inhibitors 5/01/07

Telaprevir-based Therapy for HCV May Shorten Treatment Duration from 48 to 24 Weeks for Some Genotype 1 Patients - 4/17/07

In Vitro Studies Suggest Promising Outcomes with New HCV Protease Inhibitor ACH 806 in Combination with Interferon, Telaprevir, or NM 107 4/05/07

Telaprevir Demonstrates Safety and Anti-HCV Activity in 12-week Interim Analysis 1/05/07

Telaprevir Resistance Mutations Observed in Laboratory Studies  12/05/06

Updated Results from Patients Receiving Standard HCV Therapy Following Telaprevir  12/01/06

Telaprevir plus Pegylated Interferon Suppresses Wild-type and Resistant HCV Over 14 Days
 11/03/06

Rapid Decline of HCV RNA in Patients Treated with VX-950
10/02/06

12 of 12 Patients Receiving Experimental HCV Protease Inhibitor VX 950 in Combination with Pegasys Plus Ribavirin for 28 Days Experience Undetectable HCV RNA Levels
- 5/23/06

Small Study Shows HCV RNA Levels Undetectable in 12 of 12 HCV Genotype 1 Patients after 4 Weeks of Treatment with Experimental HCV Drug VX 950 Plus Pegasys and Ribavirin - 2/10/06

Experimental Oral Protease Inhibitor VX-950 from Vertex Produces Rapid and Dramatic Reduction in HCV RNA in Combination with Pegylated Interferon Alfa-2a (Pegasys) - 1/10/06

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


copyright © 2003-2008 Janis and Friends Hepatitis C Web Site|  design )by carter

Design downloaded from Zeroweb.org: Free website templates, layouts, and tools.